“Retina Technologies’ OcuVue™ might provide an affordable end-to-end vision-screening solution for PCPs, vision-care providers and other specialists, enabling them to more effectively treat and prevent vision impairments.”

A few reasons why we think Retina Technologies OcuVue™ will make a huge difference in the providing affordable access to quality vision screening to fight needless vision loss and blindness around the world.

Equipment needed for the most basic optometrist’s office:

Up to $150,000…

“Utilizing Images of Varying Quality to Develop Device-Agnostic Diabetic Retinopathy Detection Algorithms”

“Virtual Reality Systems Provide Rapid, Non-Inferior Visual Acuity and Contrast Sensitivity Screening – A Pilot Study”

My first experience stepping into the shoes of an eye patient…

Earlier this year, during a routine annual checkup with an optometrist, I was informed that I had an abnormality that was a common indication of glaucoma. The next step would have been a visit to my primary care physician (PCP) in order to get a referral to see an ophthalmologist…

93 million adults in the United States are estimated to be at high risk for serious vision loss, but only half visited an eye doctor in the past 12 months.

$145+ billion is the annual economic impact of major vision problems among the adult population 40 years and older.

We are excited to announce that our team's first clinical trial has been accepted for publication in Translational Vision Science & Technology, a top ophthalmology journal. In this study, we demonstrated the feasibility of using virtual reality for the rapid detection of eyelid droop, including several advantages to using a more portable, accelerated system.

Retina Technologies has been invited to present our OcuVue™ Digital Vision Screening Platform in the New York Eye and Ear Infirmary of Mount Sinai booth at the AAO 2022 Conference in Chicago this year.

Our team has been invited to present the results from our head-to-head clinical trial between VR and in-office functional tests at AAO 2022, the most selective ophthalmology conference in the world.

Margo Labkovich will highlight data from our accelerated perimetry, color blindness, Amsler grid, acuity, and contrast sensitivity tests.

“While established manufacturers of diagnostic eye equipment may arguably not like the disruption, one startup company says it is offering an easy-to-use digital tool to quickly identify vision problems in patients and reports that its system may benefit both healthcare providers and patients.”

Retina Technologies was founded to solve the problem of the lack of affordable, easy-to-use vision screening tools that could provide early detection and help to eliminate needless vision loss and blindness around the world.

Our pitch will air as part of the Life Sciences, Healthcare, MedTech block on Wednesday, May 25.

Benzinga chats with one of our co-founders to learn more about Retina Technologies across a wide range of topics

As a member of the Newchip accelerator community, Retina Technologies has been selected to present our company and our game changing OcuVue™ Vision Screening Platform to their global investor network next week at their May 2022 Demo week!

200+ investors believe we can change the future of vision care.

Eye testing that reduces time, cost, and footprint?